Aberrant expression of tenascin-c and neuronatin in malignant peripheral nerve sheath tumors

European Journal of Dermatology

Volumn 20, Issue 5, 2010, Pages 580-584

  Dugu, Long ^a   Hayashida, Sayaka ^a   Nakahara, Takeshi ^a   Xie, Lining ^a   Iwashita, Yayoi ^a   Liu, Xiguang ^c   Uchi, Hiroshi ^a,b   Tateuchi, Satoshi ^a   Takahara, Masakazu ^a   Oda, Yoshinao ^d   Moroi, Yoichi ^a   Furue, Masutaka ^a,b  

^a KYUSHU UNIVERSITY   (Japan)

^b KYUSHU UNIVERSITY HOSPITAL   (Japan)

^c Heilongjiang Province Hospital   (China)

^d Department of Anatomic Pathology ^*  (Japan)

Author keywords

Immunohistolology; Ki 67; Malignant peripheral nerve sheath tumor; Neurofibroma; Neuronatin; Tenascin C

Indexed keywords

GLYCOPROTEIN; GLYCOPROTEIN NEURONATIN; KI 67 ANTIGEN; TENASCIN; TUMOR MARKER; UNCLASSIFIED DRUG;

ARTICLE; CANCER CLASSIFICATION; CELL MATURATION; CENTRAL NERVOUS SYSTEM; CONTROLLED STUDY; NERVE SHEATH TUMOR; NEUROFIBROMATOSIS; PERIPHERAL NERVE TUMOR; PERIPHERAL NERVOUS SYSTEM; PROTEIN EXPRESSION;

HUMANS; IMMUNOHISTOCHEMISTRY; KI-67 ANTIGEN; MEMBRANE PROTEINS; NERVE SHEATH NEOPLASMS; NERVE TISSUE PROTEINS; NEUROFIBROMA; TENASCIN;

EID: 77956913475     PISSN: 11671122     EISSN: 19524013     Source Type: Journal    
DOI: 10.1684/ejd.2010.0996     Document Type: Article

References (27)

1. Parrinello S, Lloyd AC. Neurofibroma development in NF1-insights into tumour initiation. Trends Cell Biol 2009; 19: 395-403.
2. Joseph NM, Mosher JT, Buchstaller J, et al. The loss of Nf1 transiently promotes self renewal but not tumorigenesis by neural crest stem cells. Cancer Cell 2008; 13: 129-40.
3. Wu J, Williams JP, Rizvi TA, et al. Plexiform and dermal neurofibromas and pigmentation are caused by Nf1 loss in desert hedgehog-expressing cells. Cancer Cell 2008; 13: 105-16.
4. Zheng H, Chang L, Patel N, et al. Induction of abnormal proliferation by nonmyelinating Schwann cells triggers neurofibroma formation. Cancer Cell 2008; 13: 117-28.
5. Mackie EJ. Molecules in focus: tenascin-C. Int J Biochem Cell Biol 1997; 29: 1133-7.
6. Jones FS, Jones PL. The tenascin family of ECM glycoproteins: structure, function, and regulation during embryonic development and tissue remodeling. Dev Dyn 2000; 218: 235-59.
7. Jones PL, Jones FS. Tenascin-C in development and disease: gene regulation and cell function. Matrix Biol 2000; 19: 581-96.
8. Järvinen TA, Kannus P, Järvinen TL, Jozsa L, Kalimo H, Järvinen M. Tenascin-C in the pathobiology and healing process of musculoskeletal tissue injury. Scand J Med Sci Sports 2000; 10: 376-82.
9. Jones PL. Extracellular matrix and tenascin-C in pathogenesis of breast cancer. Lancet 2001; 357: 1992-4.
10. Riedl S, Kadmon M, Tandara A, Hinz U, Möller P, Faissner A. Tenascin-C tissue concentration in inflammatory and neoplastic diseases of the colon mucosa. Anticancer Res 1997; 17: 3165-6.
11. Emoto K, Yamada Y, Sawada H, et al. Annexin II overexpression correlates with stromal tenascin-C overexpression: a prognostic marker in colorectal carcinoma. Cancer 2001; 92: 1419-26.
12. Dang C, Gottschling M, Roewert J, Forschner T, Stockfleth E, Nindl I. Tenascin-C patterns and splice variants in actinic keratosis and cutaneous squamous cell carcinoma. Br J Dermatol 2006; 155: 763-70.
13. Korshunov A, Golanov A, Timirgaz V. Immunohistochemical markers for intracranial ependymoma recurrence. An analysis of 88 cases. J Neurol Sci 2000; 177: 72-82.
14. Herold-Mende C, Mueller MM, Bonsanto MM, Schmitt HP, Kunze S, Steiner HH. Clinical impact and functional aspects of tenascin-C expression during glioma progression. Int J Cancer 2002; 98: 362-9.
15. Karube K, Nabeshima K, Ishiguro M, Harada M, Iwasaki H. cDNA microarray analysis of cancer associated gene expression profiles in malignant peripheral nerve sheath tumours. J Clin Pathol 2006; 59: 160-5.
16. Lévy P, Ripoche H, Laurendeau I, et al. Microarray-based identification of tenascin C and tenascin XB, genes possibly involved in tumorigenesis associated with neurofibromatosis type 1. Clin Cancer Res 2007; 13: 398-407.
17. Joseph R, Dou D, Tsang W. Neuronatin mRNA: alternatively spliced forms of a novel brain-specific mammalian developmental gene. Brain Res 1995; 690: 92-8.
18. Wijnholds J, Chowdhury K, Wehr R, Gruss P. Segment-specific expression of the neuronatin gene during early hindbrain development. Dev Biol 1995; 171: 73-84.
19. Suh YH, Kim WH, Moon C, et al. Ectopic expression of Neuronatin potentiates adipogenesis through enhanced phosphorylation of cAMP-response element-binding protein in 3T3-L1 cells. Biochem Biophys Res Commun 2005; 337: 481-9.
20. Arava Y, Adamsky K, Ezerzer C, Ablamunits V, Walker MD. Specific gene expression in pancreatic beta-cells: cloning and characterization of differentially expressed genes. Diabetes 1999; 48: 552-6.
21. Ruddock NT, Wilson KJ, Cooney MA, Korfiatis NA, Tecirlioglu RT, French AJ. Analysis of imprinted messenger RNA expression during bovine preimplantation development. Biol Reprod 2004; 70: 1131-5.
22. Uchihara T, Okubo C, Tanaka R, et al. Neuronatin expression and its clinicopathological significance in pulmonary non-small cell carcinoma. J Thorac Oncol 2007; 2: 796-801. (Pubitemid 47361019)
23. Higashi M, Tajiri T, Kinoshita Y, et al. High expressions of neuronatin isoforms in favorable neuroblastoma. J Pediatr Hematol Oncol 2007; 29: 551-6. (Pubitemid 47356809)
24. Siu IM, Bai R, Gallia GL, et al. Coexpression of neuronatin splice forms promotes medulloblastoma growth. Neuro Oncol 2008; 10: 716-24.
25. Revill K, Dudley KJ, Clayton RN, McNicol AM, Farrell WE. Loss of neuronatin expression is associated with promoter hypermethylation in pituitary adenoma. Endocr Relat Cancer 2009; 16: 537-48.
26. Korshunov A, Golanov A, Ozerov S, Sycheva R. Prognostic value of tumor-associated antigens immunoreactivity and apoptosis in medulloblastomas. An analysis of 73 cases. Brain Tumor Pathol 1999; 16: 37-44.
27. Joseph R, Tsang W, Dou D, Nelson K, Edvardsen K. Neuronatin mRNA in PC12 cells: downregulation by nerve growth factor. Brain Res 1996; 738: 32-8. (Pubitemid 26379642)